Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05286931 · ClinicalTrials.gov registry record · NA
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
A NA study of Neisseria Gonorrhoeae Infection, sponsored by University of Washington.
- Recruiting
- Registry status
- NA
- Development phase
- 1,800
- Enrollment target
- 1
- Study location
NCT05286931 is a NA study of Neisseria Gonorrhoeae Infection that is actively recruiting participants, run by University of Washington. The registered enrollment target is 1,800 participants, above the 1,139-participant average among 3 other Neisseria Gonorrhoeae Infection trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05286931, a NA study of Neisseria Gonorrhoeae Infection, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,800 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.
Conditions Studied
Interventions
- DRUG Ciprofloxacin 500 mg
Study Locations (1)
Washington
- Public Health -- Seattle & King County Sexual Health Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05286931
The ClinicalTrials.gov registry entry for NCT05286931 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,139-participant average among 3 other Neisseria Gonorrhoeae Infection trials with a reported enrollment target (58% higher). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neisseria Gonorrhoeae Infection appearing as the primary indexed condition, and to 1 intervention - of which Ciprofloxacin 500 mg is the first listed.
NCT05286931 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT05286931 about?
NCT05286931 is a clinical study titled "SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection". This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.
What is the current status of trial NCT05286931?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,800 participants. The study started on 2022-03-03. Estimated completion is 2026-12-31.
What conditions does trial NCT05286931 study?
This clinical trial studies the following conditions: Neisseria Gonorrhoeae Infection.
What interventions are being tested in trial NCT05286931?
The interventions under investigation include: Ciprofloxacin 500 mg (DRUG).
Who is sponsoring clinical trial NCT05286931?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05286931 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neisseria Gonorrhoeae Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
COMPLETED · NA
-
Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT
COMPLETED · NA
-
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.